BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine
- PMID: 35929131
- DOI: 10.1158/2159-8290.CD-22-0614
BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine
Abstract
BCL10, a key activator of NF-κB downstream of oncogenic B-cell receptor signaling, is mutated in nearly 40% of the BN2/C1 genetic subtype of diffuse large B-cell lymphoma, but how these mutations function to augment signaling and their relevance to targeted precision medicine agents remains unclear. In this issue of Cancer Discovery, Xia and colleagues demonstrate distinct mechanisms of oncogenic signaling regulation and therapeutic vulnerabilities among different recurrent BCL10 mutations. See related article by Xia et al., p. 1922 (1).
©2022 American Association for Cancer Research.
Comment on
-
BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.Cancer Discov. 2022 Aug 5;12(8):1922-1941. doi: 10.1158/2159-8290.CD-21-1566. Cancer Discov. 2022. PMID: 35658124 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials